New approaches in the treatment of bacterial infections

Recently, several new drugs for the treatment of bacterial infections have been developed. Quinupristin/dalfopristin, moxifloxacin and gatifloxacin ha ve been approved throughout the world for clinical use. Levofloxacin has be en approved for the treatment of community-acquired pneumonia caused by pen icillin-resistant Streptococcus pnuemoniae. The Food and Drug Administratio n has approved linezolid for clinical use, and new drug applications for ge mifloxacin and telithromycin were filed. Other new targets have surfaced in the quest for novel antibacterial agents.